Canakinumab

Drug Profile

Canakinumab

Alternative Names: ACZ-885; Anti-IL-1 beta monoclonal antibody; Anti-interleukin-1 beta monoclonal antibody; Antibody A; Ilaris

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Triemli hospital; University Hospital Tubingen; University Hospital Zurich
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Juvenile rheumatoid arthritis; Inflammation; Familial Mediterranean fever; Familial autosomal dominant periodic fever
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adult-onset Still's disease; Cryopyrin-associated periodic syndromes; Familial autosomal dominant periodic fever; Familial Mediterranean fever; Gouty arthritis; Juvenile rheumatoid arthritis; Peroxisomal disorders
  • Phase III Behcet's syndrome; Cardiovascular disorders
  • Phase II Abdominal aortic aneurysm; Atherosclerosis; Mucocutaneous lymph node syndrome; Osteoarthritis; Peripheral arterial occlusive disorders; Pulmonary sarcoidosis
  • Phase I Diabetic retinopathy
  • No development reported Chronic obstructive pulmonary disease
  • Discontinued Asthma; Polymyalgia rheumatica; Rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 16 Dec 2016 The Committee for Medicinal Products for Human Use recommends approval of canakinumab for the treatment of Familial autosomal dominant periodic fever, Peroxisomal disorders and Familial Mediterranean Fever in European Union
  • 11 Nov 2016 Adverse events and efficacy data from a phase III CLUSTER trial in Familial Mediterranean fever presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals
  • 08 Nov 2016 Novartis plans a phase II trial in Sickle cell anaemia in Canada, Israel and United Kingdom (NCT02961218)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top